Differential expression of HAVCR2 gene in pan-cancer: A potential biomarker for survival and immunotherapy

Differential expression of HAVCR2 gene in pan-cancer: A potential biomarker for survival and immunotherapy

T-cell immunoglobulin mucin 3 (TIM-3) has emerged as a promising immune checkpoint target in cancer therapy. However, the profile of the hepatitis A virus cellular receptor 2 (HAVCR2) gene, encoding TIM-3 expression, is still obscure, along with its role in cancer immunity and prognosis. This study...

Full description

Bibliographic Details
Main Authors:	Hetong Li, Dinglong Yang, Min Hao, Hongqi Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Genetics
Subjects:	HAVCR2 TIM-3 immune checkpoints immunotherapy pan-cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2022.972664/full

Similar Items

A Comprehensive Analysis of HAVCR1 as a Prognostic and Diagnostic Marker for Pan-Cancer
by: Sheng Liu, et al.
Published: (2022-06-01)

Corrigendum: A comprehensive analysis of HAVCR1 as a prognostic and diagnostic marker for pan-cancer
by: Sheng Liu, et al.
Published: (2024-01-01)

Markers of Immune Cell Exhaustion as Predictor of Survival in Surgically-Treated Early-Stage NSCLC
by: Laura Sellmer, et al.
Published: (2022-06-01)

A novel germline HAVCR2 (TIM-3) compound heterozygous mutation is related to hemophagocytic lymphohistiocytic syndrome in EBV-positive peripheral T-cell lymphoma (NOS) with down-regulated TIM-3 signaling
by: Yang Zhang, et al.
Published: (2022-09-01)

Case Report: HAVCR2 mutation-associated Hemophagocytic lymphohistiocytosis
by: Deli Song, et al.
Published: (2023-11-01)

Hepatitis A Virus Cellular Receptor 1 (HAVcr-1) Initiates Prostate Cancer Progression in Human Cells via Hepatocyte Growth Factor (HGF)-Induced Changes in Junctional Integrity
by: Emily A. Telford, et al.
Published: (2022-02-01)

A Pan-Cancer Analysis of the Oncogenic Role of BCL7B: A Potential Biomarker for Prognosis and Immunotherapy
by: Dinglong Yang, et al.
Published: (2022-07-01)

Prognostic and immunological role of SERPINH1 in pan-cancer
by: Huage Zhong, et al.
Published: (2022-08-01)

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
by: Mateusz Kozłowski, et al.
Published: (2022-11-01)

A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)
by: Yan Lv, et al.
Published: (2023-11-01)

Tim-3 expression and its role in hepatocellular carcinoma
by: Feifei Liu, et al.
Published: (2018-10-01)

Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapy
by: Xiashuang Zhao, et al.
Published: (2023-02-01)

RelB is a potential molecular biomarker for immunotherapy in human pan-cancer
by: Jintao Wu, et al.
Published: (2023-06-01)

Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy
by: Ya-Dong Li, et al.
Published: (2023-08-01)

TIM-3 as a Prognostic Marker and a Potential Immunotherapy Target in Human Malignant Tumors: A Meta-Analysis and Bioinformatics Validation
by: Kui Zang, et al.
Published: (2021-02-01)

Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia
by: Zi-jun Xu, et al.
Published: (2022-09-01)

Comprehensive Pan-Cancer Analysis of Senescence With Cancer Prognosis and Immunotherapy
by: Qinfei Zhao, et al.
Published: (2022-07-01)

An integrative analysis revealing POLD2 as a tumor suppressive immune protein and prognostic biomarker in pan-cancer
by: Fengyun Cong, et al.
Published: (2022-08-01)

TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS)
by: Luc M. Berclaz, et al.
Published: (2023-05-01)

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
by: Shuang Qin, et al.
Published: (2019-11-01)

CD93 Correlates With Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis
by: Zerui Zhang, et al.
Published: (2022-02-01)

An Integrated Pan-Cancer Analysis of 33 Human Cancers Reveals the Potential Clinical Implications and Immunotherapeutic Value of C-X-C Motif Chemokine Ligand 13
by: Huanyu Zhang, et al.
Published: (2022-01-01)

Pan-cancer analysis of ADAMs: A promising biomarker for prognosis and response to chemotherapy and immunotherapy
by: Bo Ma, et al.
Published: (2023-04-01)

IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma
by: Chengdong Liu, et al.
Published: (2022-12-01)

Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response
by: Zhanzhan Li, et al.
Published: (2023-05-01)

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers
by: Jiali Dai, et al.
Published: (2023-01-01)

Pan-Cancer Analysis Reveals PPRC1 as a Novel Prognostic Biomarker in Ovarian Cancer and Hepatocellular Carcinoma
by: Xingqiu Ruan, et al.
Published: (2023-04-01)

Pan-Cancer Analysis of the Oncogenic and Immunological Role of RCN3: A Potential Biomarker for Prognosis and Immunotherapy
by: Jian Ding, et al.
Published: (2022-05-01)

Radiotherapy combined with anti-CEACAM1 immunotherapy to induce survival advantage in glioma
by: Jinhu Li, et al.
Published: (2023-03-01)

Pan-Cancer Study on Protein Kinase C Family as a Potential Biomarker for the Tumors Immune Landscape and the Response to Immunotherapy
by: Alaa Abdelatty, et al.
Published: (2022-01-01)

Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model
by: Kun Zheng, et al.
Published: (2024-04-01)

MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer
by: Yong Zhou, et al.
Published: (2022-10-01)

Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker
by: Wenqing Zhang, et al.
Published: (2023-01-01)

Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
by: Maria Tampaki, et al.
Published: (2020-01-01)

Roles of HMGBs in Prognosis and Immunotherapy: A Pan-Cancer Analysis
by: Tong Lin, et al.
Published: (2021-10-01)

Pan-cancer analyses reveal the immunotherapeutic value of klotho
by: Jinghao Liang, et al.
Published: (2022-11-01)

Comprehensive analysis of the potential cuproptosis-related biomarker LIAS that regulates prognosis and immunotherapy of pan-cancers
by: Yuan Cai, et al.
Published: (2022-08-01)

Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
by: Devayani Machiraju, et al.
Published: (2021-01-01)

Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy
by: Shirin Lak, et al.
Published: (2022-12-01)

Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration
by: Xinzhu Qiu, et al.
Published: (2024-05-01)